Plain-English translation of NCT06850285 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This clinical trial is testing CD30 CAR-T, a new type of cell therapy that works by taking your own immune cells, modifying them in the laboratory to target cancer cells, and then giving them back to you. Researchers want to see if this treatment is safe and effective for people with lymphoma that has come back after other treatments or hasn't responded to previous therapy.
Many people with lymphoma find that their cancer returns or stops responding to standard treatments, leaving them with few options. This trial exists to explore whether this new cell-based approach can help patients who have exhausted other treatment options.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive a single infusion of the modified cell therapy. The study will involve collecting some of your blood cells first, which are then sent to a laboratory to be modified and grown. While the cells are being prepared, you may receive chemotherapy to prepare your body. Once the cells are ready, you will receive them back as an infusion, and then the research team will monitor you closely over time with blood tests and imaging to see how you respond and to watch for any side effects.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China
Sponsor
Shanxi Bethune Hospital
Enrollment target
~15 participants
Started
September 2025
Primary completion
June 2028
Age range
15 Years – 80 Years
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
jia wei
Shanxi Bethune Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.